Candin Market Forecast to 2030: Nielsen BioSciences Controls Entire Market, Hospitals Represent 61% of Demand

candin_global_market_report_Comp_And_Segment

candin_global_market_report_Regions_And_Drivers

candin_global_market_report

The Business Research Company's Candin Market Report 2026 – Market Size, Trends, And Global Forecast 2026-2035

LONDON, GREATER LONDON, UNITED KINGDOM, October 8, 2026 /EINPresswire.com/ -- "The candin market is a specialized segment within the pharmaceutical industry, primarily led by global companies focusing on antifungal therapies. These key players are enhancing their market presence by developing advanced antifungal formulations, improving drug delivery methods, and ensuring compliance with stringent manufacturing and regulatory standards. Their efforts aim to address the increasing incidence of fungal infections, improve treatment outcomes, and maintain high-quality products, all while expanding research activities and forming strategic alliances in this rapidly evolving therapeutic area.

Market Leadership in the Candin Market
Nielsen BioSciences Inc. stands out as the dominant force in the candin market, holding an exclusive 100% share of global sales in 2025 according to The Business Research Company. This company’s antifungal therapeutics division is deeply involved in providing drugs, diagnostic tools, and pharmaceutical products for managing candidiasis and other invasive fungal infections, all while adhering to rigorous efficacy, safety, and regulatory standards.

Request A Free Sample Of The Candin Market Report
https://thebusinessresearchcompany.com/sample_request?id=35145663&type=smp&name=Candin%20Market%20Report%202026&utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Oct_PR

Market Share Distribution in the Candin Industry
The Business Research Company characterizes the candin market as moderately fragmented, with Nielsen BioSciences Inc. capturing the entire market revenue in 2025. Entry barriers such as strict pharmaceutical quality demands, complicated drug development processes, and regulatory approval challenges contribute to this dynamic. Nielsen BioSciences maintains its leadership by leveraging a diverse antifungal product portfolio, robust research and development capabilities, a well-established commercialization network, and ongoing innovation. As the demand for effective antifungal treatments rises, strategic partnerships, product innovation, clinical advancements, and geographic expansion are expected to solidify the position of leading firms.

Notable Market Leader and Its Share
- Nielsen BioSciences Inc. — 100% market share in 2025

Access The Detailed Candin Market Report Here
https://thebusinessresearchcompany.com/report/candin-global-market-report?utm_source=EINPresswire&utm_medium=Paid&utm_campaign=Oct_PR

Emerging Trends Shaping the Candin Market
The candin market is witnessing a shift with the rise of immunotherapy-based treatments. These therapies offer long-lasting wart clearance, enhance cell-mediated immune responses, and provide less invasive alternatives to traditional methods.
For example, in May 2026, Nielsen BioSciences announced positive results from a Phase 3 clinical trial of CANDIN for common wart treatment. The findings demonstrated improved wart resolution and support the progression toward regulatory approval, expanding treatment options for HPV-induced skin infections.

Effective Strategies in the Candin Market
Key approaches in this market include creating Candin skin test antigen solutions that enhance immune response evaluation and diagnostic accuracy. Expanding clinical applications strengthens immunology and infectious disease diagnostics, while the adoption of advanced laboratory technologies improves test standardization and precision.

Market Size and Industry Scope of the Candin Sector
The candin market is projected to exceed $0.005 billion by 2030. This represents a small fraction of its parent Dermatology Drugs market, which is expected to reach around $97 billion by the same year. Within the larger Pharmaceuticals industry, forecasted to hit $2,496 billion by 2030, candin occupies a minor segment, accounting for approximately 0.0002%. A compound annual growth rate (CAGR) of 5% is anticipated for the candin market leading up to 2030.

Regional Market Projections for Candin
North America is set to be the largest regional market for candin in 2030, valued at $0.0039 billion, increasing slightly from $0.0038 billion in 2025 at a CAGR of 1%. This growth reflects consistent demand from mature industries, well-established production and distribution networks, and stable supply agreements across the United States and Canada.

The United States will remain the largest country market for candin, projected at $0.0038 billion in 2030, growing modestly from $0.0037 billion in 2025 at a 0.4% CAGR. This steady increase is driven by niche industrial applications, established domestic manufacturing, and ongoing demand in specialty chemical formulations.

Dominant Product Segments within the Candin Market
The candin market is primarily segmented by product into hospitals and specialty clinics. Hospitals are expected to dominate in 2030, accounting for 61% of the market, or $0.003 billion. This is due to hospitals’ preference for administering specialized antifungal treatments, availability of trained healthcare professionals, inpatient care for vulnerable patients, established pharmacy procurement systems, and adherence to clinical pathways for managing invasive fungal infections.

Additional Market Segmentation Details
- Patient demographics include immunocompromised patients (such as oncology and transplant patients), infectious disease and HIV/AIDS patients, and pediatric and geriatric groups.
- Indications cover candidiasis and thrush.
- Distribution channels encompass hospital pharmacies, retail pharmacies, and online pharmacies.

Main Factors Propelling Growth in the Candin Market
Several key drivers are expected to fuel the global candin market through 2030.

Rising Incidence of Fungal Infections and Candidiasis
An aging population, increasing rates of diabetes, prolonged antibiotic use, cancer treatments, and organ transplants contribute to a growing number of individuals at risk for Candida infections. This trend boosts the need for accurate diagnostic tools to assess immune responses. Candin is frequently used as a diagnostic skin test antigen to evaluate cell-mediated immunity and delayed hypersensitivity. With healthcare providers prioritizing early diagnosis and immune evaluation, this factor is expected to add about 1.5% growth annually to the market.

Expanding Population of Immunocompromised Patients
Patients with compromised immune systems due to HIV/AIDS, cancer, autoimmune conditions, organ transplants, chemotherapy, or immunosuppressive therapy often require immune competency testing. Candin skin tests help assess immune function in these groups. As this patient population rises globally, so does demand for immune response testing, driven by hospitals integrating immune assessments into routine care for high-risk individuals. This factor is projected to contribute around 1.0% annual market growth.

Increasing Use of Diagnostic Skin Tests in Healthcare Settings
Diagnostic skin tests like candin are minimally invasive, cost-effective, and easier to administer compared to complex laboratory assays, providing essential information on immune function. Hospitals are adopting such tests more frequently to detect and monitor immune deficiencies and immunosuppressive disorders, supported by expanded healthcare infrastructure, clinical guidelines emphasizing early detection, and preventive care. This trend is expected to add roughly 0.8% growth annually to the market.

Outlook on Growth Opportunities in the Candin Market by 2030
Hospitals and specialty clinics together represent the most promising areas for market expansion, expected to contribute over $0.002 billion in additional market value by 2030. Each segment is projected to grow by about $0.001 billion between 2025 and 2030. Growth drivers include heightened awareness of invasive fungal infection management, development of targeted antifungal therapies, improved access to infectious disease care, early intervention strategies, and enhanced infection surveillance and antimicrobial stewardship programs.

Supply Chain and Customer Base Overview in the Candin Market
The candin supply chain includes raw material suppliers such as Nielsen BioSciences Inc., Thermo Fisher Scientific Inc., Merck KGaA, Bio-Rad Laboratories Inc., Lonza Group AG, Sartorius AG, Fujifilm Irvine Scientific, Bio-Techne Corporation, Charles River Laboratories International Inc., WuXi AppTec Co., Ltd., Eurofins Scientific SE, and others.

Wholesalers and distributors encompass companies like McKesson Corporation, Cardinal Health Inc., Cencora Inc., Henry Schein Inc., Medline Industries LP, Owens & Minor Inc., Morris & Dickson Co. LLC, Anda Inc., Concordance Healthcare Solutions LLC, and more.

Key end users include prominent healthcare providers such as Mayo Clinic, Cleveland Clinic, Johns Hopkins Hospital, Massachusetts General Hospital, Stanford Health Care, University of California San Francisco Health, Memorial Sloan Kettering Cancer Center, Mount Sinai Health System, Kaiser Permanente, HCA Healthcare Inc., Quest Diagnostics Incorporated, and several others.

Major Players Dominating the Candin Market
The primary company operating within the candin market is Nielsen BioSciences Inc., maintaining its leadership through innovation and comprehensive product offerings.

Expanded capabilities in our 2026 market reports:

• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel-based forecasting dashboards
• Market hotspots infographics
• Key technologies and future trend analysis
• Updated graphics and tables

About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a renowned market intelligence firm specializing in company, market, and consumer research. With over 30,000+ reports spanning 27 industries and more than 60 geographies, their insights draw upon 1.5 million datasets, extensive secondary research, and interviews with industry leaders. They offer a range of tailored research packages such as Market Entry, Competitor Tracking, and Supplier & Distributor packages.

Disclaimer: The information provided by TBRC Business Research Pvt Ltd is gathered in good faith from primary and secondary sources, though accuracy cannot be fully guaranteed. The company disclaims liability for any actions taken based on its findings, which are intended as estimates and opinions rather than definitive facts or investment advice.

Contact Information
The Business Research Company
Americas: +1 310-496-7795
Europe: +44 7882 955267
Asia & Others: +44 7882 955267 / +91 8897263534
Email: marketing@tbrc.info

Follow on LinkedIn: https://in.linkedin.com/company/the-business-research-company"

Oliver Guirdham
The Business Research Company
+44 7882 955267
info@tbrc.info
Visit us on social media:
LinkedIn
Facebook
X